We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/7/2020 18:27 | Onceaday, Correct. There's plenty of room for more than one player here. And differences/advantag | small crow | |
28/7/2020 16:26 | If you read into the detail of yhe results, you will find it was a triple arm trial - they used a sham (no dose), low dose and high dose arm. Only the high dose arm showed meaningfull efficacy andonly a sub population showed comparable efficacy to RENE's ph2a results.. RENE will treat a further 9 patients at double dose in the ph2a extension trial. The fact that jCute had good results with the same type of hRPC cell validates RENEs work so far amd adds value. I think there will be a number of large pharmas keeping a very close eye (excuse the pun) on the extension trial. It's open label,unlike the jCyte ph2b, so they can announce tesults as they go. Biotech investment is all about timing - it can take years (decades) for value inflection - it could be that RENE's time has finally arrived. | onceaday | |
27/7/2020 19:48 | Well that new bloke brought in to do deals sure ain't cutting it is he ? | martinfrench | |
27/7/2020 16:17 | There are quite a few US players looking to buy into RP drugs and only two companies who are well advanced in that field and happy to outlicence their drugs. I think jCyte success will only increase interest in a deal with Reneuron and the regulators doesn't seem to have a problem with only 10-20 patients in their study. | pawelkordala | |
27/7/2020 15:57 | Oh well, makes rene look to be a loser. 74 patients as against 10! Much larger trial. Exozome the only hope? | rayrac | |
27/7/2020 13:18 | hxxps://www.business | crt131 | |
21/7/2020 15:00 | Funding round soon | sambocoole | |
14/7/2020 17:00 | He's got quite some money. | small crow | |
14/7/2020 15:58 | Whatever, that’s quite a holding. | rayrac | |
14/7/2020 14:27 | Typo or 15 months 5. Date on which the threshold was crossed or reached: 5 March 2019 hxxps://www.marketsc | xow98 | |
14/7/2020 14:21 | Anyone know how that investor gets away with not filing until over 3 months after change? | small crow | |
29/6/2020 11:37 | Encouraging results. It will be interesting to see the results come in from the new sample of patients once things begin - lessons should have been learned from sample 1 and so, hopefully, even more convincing improvements. | small crow | |
29/6/2020 08:07 | martin - 18 months is only 1 patient hence not really comparable with the others - he's obviously done exceptionally well on the treatment. Results remain very good for all patients (except those who suffered surgical problems obviously) but most striking to me is the improvement in the untreated eyes. Normally they would be expected to continue deteriorating to more or less full blindness, but here they're also improving quite markedly. Let's hope it continues. | supernumerary | |
29/6/2020 06:39 | Pretty amazing jump from 12 to 18 months, if I have read it correctly on phone. Also very pleased that one of the blinded patients got back to baseline | martinfrench | |
29/6/2020 06:17 | More good news today, should help support the sp | ayl30 | |
28/6/2020 10:29 | Lauders, Thanks for that. I think exosomes will turnout to be very useful and valuable, but I've been wrong before! Let's hope we are inside the tent. | small crow | |
28/6/2020 05:37 | Been having a look at the exosome companies and deals out of my own personal interest: 1) Sarepta Inks Agreement With Codiak to Develop Gene Therapies (already mentioned here) - 2) InnoCan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus. CBD-Loaded Exosomes hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. 3) British biotech Evox Therapeutics has signed a collaboration deal worth up to €1.1B with US big pharma Eli Lilly to develop RNA drugs that are delivered in exosomes to the brain to treat neurological diseases. 4) Exopharm (ASX:EX1) reveals promising Plexaris anti-cancer results. + The company combined a typical lung cancer treatment drug called doxorubicin with its Plexaris exosome product to create a new treatment, dubbed Plexodox. 5) VivaZome Therapeutics and the University of Adelaide have entered into a series of agreements encompassing licensing of technology, access to stem cells and conduct of research, all in support of VivaZome’s mission to develop and commercialise exosome-based therapeutics. 6) MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development. + EVs, especially exosomes, have emerged as a novel therapeutic with their roles in intercellular communications. 7) Avalon GloboCare Partners with HydroPeptide. + Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically-integrate 8) Orgenesis has added muscle-derived stem cells to its offering through a manufacturing joint venture with Revatis. The partnership will supply developers of autologous cell therapies with exosomes and other cellular products obtained from muscle-derived mesenchymal stem cells (mdMSCs). 9) Evox and Takeda sign deal to collaborate on rare disease treatments. + The targeted and non-targeted exosomes offer a highly differentiated platform with the potential to enhance tissue delivery for a variety of payloads like mRNA and proteins. 10) Exosome specialist Exopharm (EX1) has reported some strong results for its Cevaris product in treating erectile dysfunction (ED). These are just the first ten I found and there seem to be many more out there. Looks like this could be a very exciting place to be as RENE inks new deals and hopefully develops exosomes further for the benefit of many patients. This is also worth a read: | lauders | |
25/6/2020 11:28 | ReNeuron Group inks research evaluation deal with US firm - At 12.26 +3.50 (2.64%) 25 Jun, 11:48 BST | spurslegend1 | |
25/6/2020 08:05 | Yes that's the idea. They are part of cells in the body which carry payloads within the cell. RENE have managed to functionalist them as delivery systems.. | bonzo | |
25/6/2020 07:57 | I was much struck by this report. Not directly relevant, but I imagine there are researchers in labs all over the world trying to replicate these results. Could exosomes be used as carriers? | supernumerary | |
25/6/2020 07:50 | ??? An effective delivery system to the brain is a very valuable asset... | bonzo | |
25/6/2020 07:31 | There we are! But like Big Mac burgers, the smells not bad, but the taste...urgh | rayrac | |
24/6/2020 10:58 | I have the sense that RENE is trying to go in this direction given the limits of its cash balance and an inability to self-finance its research through to marketable products. A similar deal like this would surely raise RENE's credibility with investors. | dickbush | |
23/6/2020 21:43 | Big money still being paid for exosomes: Gene therapy could be a game changer for various diseases, but it can be hobbled by its packaging, most often a virus to which some people are naturally immune. Sarepta Therapeutics is on the hunt for alternatives, and its latest target is a system the body’s cells use to communicate with each other: exosomes. It is teaming up with Codiak Biosciences to develop engineered exosomes that can deliver gene therapy, gene editing or RNA-based treatments—all of which Sarepta is already working on. Under the two-year deal, Codiak will reel in up to $72.5 million in upfront and near-term license fees along with research funding, the pair said in a statement Monday. As usual, Codiak stands to pick up “significant&r [ ... ] | supernumerary | |
19/6/2020 10:21 | Exosome program is coming to the fore and we are in an increasing number of discussions with potential collaborators RENE is one for the patient, but hopefully it will be very rewarding for patients, the company and investors when things come good! Have to think positive! | lauders |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions